07:00 , Mar 9, 2015 |  BC Week In Review  |  Company News

Mayne Pharma, Actavis deal

Actavis returned to Mayne rights to Doryx doxycycline and related assets for $50 million. Doryx is a delayed-release pelletized doxycycline that is approved to treat severe acne. Actavis will package, distribute and promote Doryx until...
07:00 , Apr 22, 2013 |  BC Week In Review  |  Clinical News

Doryx doxycycline hyclate delayed-release tablet regulatory update

FDA approved a 200 mg dose of tetracycline oral antibiotic Doryx doxycycline hyclate delayed-release tablet from Mayne's U.S. marketing partner Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland). Warner Chilcott plans to launch the dose in July....
07:00 , May 7, 2012 |  BC Week In Review  |  Company News

Warner Chilcott, Impax, Mylan infectious news

Warner Chilcott said the U.S. District Court for the District of New Jersey ruled in favor of Mylan and Impax in a patent infringement suit brought by Warner Chilcott related to a generic version of...
08:00 , Dec 19, 2011 |  BC Week In Review  |  Company News

Mayne Pharma, Warner Chilcott, Mylan infectious news

Warner Chilcott said the U.S. Court of Appeals for the Federal Circuit vacated a preliminary injunction granted by the U.S. District Court for the District of New Jersey prohibiting Mylan from selling a generic version...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Clinical News

Doryx doxycycline hyclate delayed-release tablet regulatory update

FDA accepted for filing a Citizen's Petition from Mayne's marketing partner Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland) asking the agency not to grant final approval of ANDAs for generic versions of 150 mg Doryx doxycycline...
07:00 , Oct 5, 2009 |  BC Week In Review  |  Company News

HalcyGen, Hospira deal

HalcyGen will acquire Hospira's Mayne Pharma International Pty. Ltd. subsidiary for US$15 million in cash, plus earn outs over six years. The deal gives HalcyGen full control over SUBA-Itraconazole, which it licensed from Mayne in...